ATLANTIC DIP: Insulin Therapy for women with IADPSG-diagnosed Gestational Diabetes Mellitus. Does it work?

Bogdanet, Delia; Egan, Aoife M.; Reddin, Catriona; Kgosidialwa, Oratile; Kirwan, Breda; Carmody, Louise; Dunne, Fidelma

doi:10.1210/jc.2016-2911

Cited by 11 publications

(12 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since the new recommendation of the IADPSG, several studies reported that treatment based on the IADPSG criteria improved pregnancy outcomes. However, those studies were retrospective, and the comparison groups were women with normal glucose tolerance or GDM determined through different glucose cut-off values or diagnostic methods, such as 100 g OGTT [8][9][10]. A recent study reported that no differences were noted between untreated and treated patients diagnosed by the IADPSG criteria [11].…”

Section: Treatment Of Gestational Diabetes Diagnosed By the Iadpsg Crmentioning

confidence: 99%

Treatment of gestational diabetes diagnosed by the IADPSG criteria decreases excessive fetal growth

et al. 2020

View full text Add to dashboard Cite

Objective We evaluated the effect on treatment using the new International Association of Diabetes and Pregnancy Study Group (IADPSG) criteria for gestational diabetes mellitus (GDM) diagnosis. Methods Singleton pregnant women whose plasma glucose levels were ≥140 mg/dL on the 50 g glucose challenge test (GCT) underwent 75 g oral glucose tolerance for GDM diagnosis. During the first half of the study period, GDM was diagnosed using 2 abnormal values by Carpenter-Coustan (C-C) criteria. In the second half of the study period, 1 or more abnormal values by IADPSG criteria were used for GDM diagnosis. Pregnant women were classified into 5 groups: normal 50 g GCT, positive 50 g GCT but non-GDM, GDM by IADPSG criteria and non-treated, GDM by IADPSG criteria and treated, GDM by CC criteria and treated. The odds ratios (ORs) for large for gestational age (LGA) and macrosomia were analyzed. Results Of the 2,678 patients, the frequency of GDM diagnosed by CC and IADPSG criteria was 2.6% and 7.5%. ORs (95% confidence intervals [CIs]) for LGA and macrosomia in the group with GDM by IADPSG criteria and non-treated were 2.81 (95% CI, 1.47-5.38) and 2.84 (95% CI, 1.08-7.47). The risk of LGA and macrosomia did not increase in the group with GDM by IADPSG criteria and treated. Conclusion The risk of LGA and macrosomia for mild GDM diagnosed solely by IADPSG criteria depends on whether they are treated or not. Treatment of GDM based on IADPSG criteria reduces the risk of excessive fetal growth.

show abstract

Section: Treatment Of Gestational Diabetes Diagnosed By the Iadpsg Crmentioning

confidence: 99%

Treatment of gestational diabetes diagnosed by the IADPSG criteria decreases excessive fetal growth

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Thus, there is need for improved targeted interventions that have been shown to be of benefit, such as intensified treatment 14 or screening for gestational hyperglycaemia in the first trimester, that is advised by some groups and guidelines 4, 13 . Facilitating and improving national birth registries could also assist us in answering the unresolved points addressed here.…”

Section: Resultsmentioning

confidence: 99%

“…before typical time for OGTT testing, are usually considered as more glucose intolerant than those with onset at gestational week 24-28 or later 13 . The influence of overweight in women with GDM varies, but women with high BMI before pregnancy are overrepresented in most GDM cohorts 14,15 . Both MODY and type 1 diabetes may become manifest during pregnancy 16 , which adds to the complexity of diagnosing and treating hyperglycaemia in pregnancy.…”

mentioning

confidence: 99%

The diversity of gestational diabetes: a therapeutic challenge

Qvigstad

2018

European Journal of Endocrinology

View full text Add to dashboard Cite

Metformin as the first drug of choice for glucose lowering in gestational diabetes (GDM) is still controversial, despite recent publications reporting similar outcomes in comparison to insulin, both for offspring and mothers. The use of metformin during pregnancy is increasing and several recent guidelines recommend metformin use in GDM pregnancies. Background, current metformin use and unresolved concerns are discussed in the context of the article from Gante and coworkers.

show abstract

“…It is also interesting to explore the cross-talk between GDM and these conditions at the protein level. Finally, many studies also found that the treatment of GDM patients did not significantly reduce some of the maternal and fetal outcomes such as subsequent diabetes, metabolic syndrome, perinatal death, neonatal hypoglycemia, and childhood obesity [ 13 , 75 – 77 ]. Thus, it is necessary to develop prognostic markers for postpartum and long-term outcomes in treated patients.…”

Section: Considerations and Recommendations For Future Studiesmentioning

confidence: 99%

“…Moreover, current treatments may have limited effects on early GDM (diagnosed in high-risk women at <24 weeks of gestation) [12]. A recent study also showed that the incidences of neonatal hypoglycemia and polyhydramnios remain high after insulin treatment [13]. Thus, GDM has become a serious public health problem that increases health care costs during and post pregnancy [14].…”

Section: Introductionmentioning

confidence: 99%

A Critical Review of Proteomic Studies in Gestational Diabetes Mellitus

Zhou

Huang

Wei

et al. 2020

Journal of Diabetes Research

View full text Add to dashboard Cite

Gestational diabetes mellitus is a progressive and complex pregnancy complication, which threatens both maternal and fetal health. It is urgent to screen for specific biomarkers for early diagnosis and precise treatment, as well as to identify key moleculars to better understand the pathogenic mechanisms. In the present review, we comprehensively summarized recent studies of gestational diabetes using mass spectrometry-based proteomic technologies. Focused on the entire experimental design and proteomic results, we showed that these studies have covered a broad range of research contents in terms of sampling time, sample types, and outcome associations. Although most of the studies only stayed in the stage of initial discovery, several proteins were further verified to be efficient for disease diagnosis. Functional analysis of all the combined significant proteins also showed that a small number of proteins are known to be involved in the regulation of insulin or indirect signaling pathways. However, many factors such as diagnostic criteria, sample processing, proteomic method, and statistical method can greatly affect the identification of reproducible and reliable protein candidates. Thus, we further provided constructive suggestions and recommendations for carrying out proteomic or follow-up studies of gestational diabetes or other pregnancy complications in the future.

show abstract

ATLANTIC DIP: Insulin Therapy for women with IADPSG-diagnosed Gestational Diabetes Mellitus. Does it work?

Cited by 11 publications

References 32 publications

Treatment of gestational diabetes diagnosed by the IADPSG criteria decreases excessive fetal growth

Treatment of gestational diabetes diagnosed by the IADPSG criteria decreases excessive fetal growth

The diversity of gestational diabetes: a therapeutic challenge

A Critical Review of Proteomic Studies in Gestational Diabetes Mellitus

Contact Info

Product

Resources

About